{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:05:59Z","timestamp":1784912759598,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.coph.2026.102635","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T23:12:26Z","timestamp":1778368346000},"page":"102635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Alopecia areata: Mechanisms, targeted therapies, and translational challenges"],"prefix":"10.1016","volume":"89","author":[{"given":"Virender","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8016-693X","authenticated-orcid":false,"given":"Pawan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2026.102635_bib1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/bjd\/ljae058","article-title":"Global, regional and national epidemiology of alopecia areata: a systematic review and modelling study","volume":"191","author":"Jeon","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2026.102635_bib2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/bjd\/ljae307","article-title":"Lifetime incidence and healthcare disparities in alopecia areata: a UK population-based cohort study","volume":"191","author":"Thompson","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2026.102635_bib3","series-title":"The color atlas and synopsis of family medicine","author":"Usatine","year":"2019"},{"key":"10.1016\/j.coph.2026.102635_sref4","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70182","article-title":"Alopecia areata: pathogenesis, diagnosis, and therapies","volume":"6","author":"Ma","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.coph.2026.102635_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1573929","article-title":"Treatment outcomes and considerations for topical immunotherapy in patients with alopecia totalis and alopecia universalis","volume":"12","author":"Hitaka","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.coph.2026.102635_bib6","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjd.18883","article-title":"The alopecia areata investigator global assessment scale: a measure for evaluating clinically meaningful success in clinical trials","volume":"183","author":"Wyrwich","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2026.102635_bib7","doi-asserted-by":"crossref","first-page":"adv44153","DOI":"10.2340\/actadv.v105.44153","article-title":"Is spontaneous regrowth in alopecia areata possible: a systematic review and meta-analysis of placebo-controlled studies","volume":"105","author":"Jastrz\u0105b-Mi\u015bkiewicz","year":"2025","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.coph.2026.102635_bib8","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1021\/pr100422u","article-title":"Trichohyalin is a potential major autoantigen in human alopecia areata","volume":"9","author":"Leung","year":"2010","journal-title":"J Proteome Res"},{"key":"10.1016\/j.coph.2026.102635_bib9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/1523-1747.ep12375477","article-title":"Antibodies to hair follicles in alopecia areata","volume":"102","author":"Tobin","year":"1994","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2026.102635_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.890027","article-title":"Autoantigen discovery in the hair loss disorder, alopecia areata: implication of post-translational modifications","volume":"13","author":"Jadeja","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2026.102635_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1243556","article-title":"Inhibition of T-cell activity in alopecia areata: recent developments and new directions","volume":"14","author":"Passeron","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2026.102635_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.det.2024.09.001","article-title":"Innovation in alopecia areata","volume":"43","author":"Kalil","year":"2025","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.coph.2026.102635_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/pde.15842","article-title":"Pathophysiology of alopecia areata in the pediatric patient","volume":"42","author":"Fitzhugh","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.coph.2026.102635_bib14","article-title":"Integrating psychological support and topical therapy for the effective management of stress-induced alopecia areata: a case report","volume":"17","author":"Alotiby","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.coph.2026.102635_bib15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.25259\/IJDVL_1093_2022","article-title":"Janus kinase inhibitors for alopecia areata: a narrative review","volume":"89","author":"Haughton","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.coph.2026.102635_bib16","article-title":"Alopecia areata treatment: past, present, and future","volume":"5","author":"Jolkovsky","year":"2024","journal-title":"Dermatol Rev"},{"key":"10.1016\/j.coph.2026.102635_sref17","article-title":"Alopecia areata: understanding the pathophysiology and advancements in treatment modalities","volume":"17","author":"Abarca","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.coph.2026.102635_bib18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","article-title":"Alopecia areata: an update on etiopathogenesis, diagnosis, and management","volume":"61","author":"Zhou","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.coph.2026.102635_bib19","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.3390\/ijms25115652","article-title":"Deciphering the complex immunopathogenesis of alopecia areata","volume":"25","author":"\u0160uti\u0107 Udovi\u0107","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2026.102635_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.alit.2019.07.009","article-title":"Plasmacytoid dendritic cells as a possible key player to initiate alopecia areata in the C3H\/HeJ mouse","volume":"69","author":"Ito","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.coph.2026.102635_bib21","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","article-title":"Efficacy and safety of deuruxolitinib in adults with alopecia areata: results from a phase 3 randomized controlled trial","volume":"91","author":"King","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2026.102635_bib22","article-title":"Novel potential therapeutic targets of alopecia areata","volume":"14","author":"Xu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2026.102635_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1281660","article-title":"Gut microbiome, metabolome and alopecia areata","volume":"14","author":"Liu","year":"2023","journal-title":"Front Microbiol"},{"key":"10.1016\/j.coph.2026.102635_sref24","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2025.100363","article-title":"Cutaneous and gut dysbiosis in alopecia areata: a review","author":"Burma","year":"2025","journal-title":"JID Innov"},{"key":"10.1016\/j.coph.2026.102635_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1641918","article-title":"Overlapping features of atopic dermatitis and alopecia areata: from pathogenesis to treatment","volume":"16","author":"Cheng","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2026.102635_bib26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s44368-025-00013-8","article-title":"Alopecia areata: a comprehensive review of clinical, immunologic, and genetic perspectives","volume":"2","author":"Akbaba","year":"2025","journal-title":"Discov Immun"},{"key":"10.1016\/j.coph.2026.102635_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103339","article-title":"Biomarkers in alopecia areata: a systematic review and meta-analysis","volume":"22","author":"Zaaroura","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coph.2026.102635_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12911-025-02853-8","article-title":"Identifying effective immune biomarkers in alopecia areata diagnosis based on machine learning methods","volume":"25","author":"Zhou","year":"2025","journal-title":"BMC Med Inf Decis Making"},{"key":"10.1016\/j.coph.2026.102635_bib29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/pde.15822","article-title":"Systemic therapies for pediatric alopecia areata","volume":"42","author":"Kalil","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.coph.2026.102635_bib30","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamadermatol.2023.2581","article-title":"Clinical outcomes for uptitration of baricitinib therapy in patients with severe alopecia areata: a pooled analysis of the BRAVE-AA1 and BRAVE-AA2 trials","volume":"159","author":"Ko","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coph.2026.102635_bib31","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/pde.15378","article-title":"Efficacy and safety of ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO phase 2b\/3 randomized, double-blind, placebo-controlled trial","volume":"40","author":"Hordinsky","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.coph.2026.102635_bib32","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s40265-023-01928-y","article-title":"Ritlecitinib: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2026.102635_bib33","series-title":"Late-breaking phase 3 data at AAD 2023 show oral investigational medicine deuruxolitinib significantly improved scalp hair regrowth in alopecia areata","year":"2023"},{"key":"10.1016\/j.coph.2026.102635_bib34","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000544868","article-title":"Upadacitinib for alopecia: current evidence and clinical insights","volume":"11","author":"Stirrat","year":"2025","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.coph.2026.102635_bib35","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/jocd.15896","article-title":"Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib","volume":"23","author":"Huang","year":"2024","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.coph.2026.102635_bib36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jaad.2024.09.073","article-title":"A phase 2a trial of brepocitinib for cicatricial alopecia","volume":"92","author":"David","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2026.102635_bib37","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.063","article-title":"A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib in adult patients with moderate-to-severe alopecia areata","volume":"89","author":"Zhou","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2026.102635_bib38","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/ajh.26709","article-title":"Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-na\u00efve patients with myelofibrosis: results of a phase II trial","volume":"97","author":"Zhang","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.coph.2026.102635_bib39","series-title":"StatPearls [Internet]","article-title":"Deucravacitinib","author":"Kalola","year":"2025"},{"key":"10.1016\/j.coph.2026.102635_bib40","first-page":"234","article-title":"Hair regain in a patient with alopecia universalis and psoriasis vulgaris under deucravacitinib therapy","volume":"23","author":"Jonas","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.coph.2026.102635_bib41","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.3390\/ijms25179236","article-title":"Mesenchymal stem cell therapy in alopecia areata: visual and molecular evidence from a mouse model","volume":"25","author":"Park","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2026.102635_bib42","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1186\/s13287-021-02614-0","article-title":"Hair follicle-derived mesenchymal stem cells decrease alopecia areata mouse hair loss and reduce inflammation around the hair follicle","volume":"12","author":"Deng","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.coph.2026.102635_bib43","unstructured":"Clinical application of stem cell educator therapy in alopecia areata. ClinicalTrials.gov, 2025, National Library of Medicine; Bethesda (MD), Available from: https:\/\/clinicaltrials.gov\/study\/NCT04011748 (Accessed 18 August 2025)."},{"key":"10.1016\/j.coph.2026.102635_sref44","doi-asserted-by":"crossref","DOI":"10.5070\/D330564423","article-title":"Light-based therapies in the treatment of alopecia","volume":"30","author":"Oh","year":"2024","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.coph.2026.102635_bib45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14764172.2016.1248440","article-title":"A review on laser and light-based therapies for alopecia areata","volume":"19","author":"Mlacker","year":"2017","journal-title":"J Cosmet Laser Ther"},{"key":"10.1016\/j.coph.2026.102635_bib46","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s10103-017-2306-7","article-title":"Efficacy of fractional lasers in treating alopecia: a literature review","volume":"32","author":"Perper","year":"2017","journal-title":"Laser Med Sci"},{"key":"10.1016\/j.coph.2026.102635_bib47","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1111\/jocd.16459","article-title":"Progress of clinical research on fractional laser treatment of androgenetic alopecia: a review article","volume":"23","author":"Li","year":"2024","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.coph.2026.102635_bib48","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s10103-019-02890-6","article-title":"A novel 311 nm titanium:sapphire laser therapy for alopecia areata: a pilot study of 19 patients","volume":"35","author":"Lee","year":"2020","journal-title":"Laser Med Sci"},{"key":"10.1016\/j.coph.2026.102635_bib49","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1080\/09546634.2019.1687819","article-title":"Meta-analysis of 308-nm excimer laser therapy for alopecia areata","volume":"32","author":"Gupta","year":"2021","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.coph.2026.102635_bib50","article-title":"Fractional laser-assisted hair regrowth and microneedling for the treatment of alopecia areata: a review","volume":"11","author":"Dabek","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.coph.2026.102635_bib51","doi-asserted-by":"crossref","DOI":"10.1007\/s10103-025-04284-3","article-title":"Alopecia areata treated using CO2 fractional laser with different parameters","volume":"40","author":"Wu","year":"2025","journal-title":"Laser Med Sci"},{"key":"10.1016\/j.coph.2026.102635_bib52","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.2174\/1381612824666180807120017","article-title":"Current non-viral siRNA delivery systems as a promising treatment of skin diseases","volume":"24","author":"Rosa","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.coph.2026.102635_sref53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-45594-2","article-title":"Gene therapy for alopecia in type II rickets model rats using vitamin D receptor-expressing adenovirus vector","volume":"13","author":"Kise","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2026.102635_sref54","doi-asserted-by":"crossref","first-page":"7612","DOI":"10.3390\/ijms25147612","article-title":"Delivery strategies of siRNA therapeutics for hair loss therapy","volume":"25","author":"Jin","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2026.102635_bib55","unstructured":"E. Andrus, Phase 1b study of rezpegaldesleukin in moderate-to-severe atopic dermatitis met clinical efficacy endpoints. https:\/\/www.dermatologytimes.com\/view\/phase-1b-study-of-rezpegaldesleukin-in-moderate-to-severe-ad-met-clinical-efficacy-endpoints; Dermatology Times, 2023 (Accessed 15 April 2026)."},{"key":"10.1016\/j.coph.2026.102635_bib56","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2468312","article-title":"Targeting \u03b3c family cytokines with biologics: current status and future prospects","volume":"17","author":"Bick","year":"2025","journal-title":"mAbs"},{"issue":"Suppl 1","key":"10.1016\/j.coph.2026.102635_bib57","doi-asserted-by":"crossref","first-page":"i225","DOI":"10.1093\/ecco-jcc\/jjad212.0121","article-title":"Rosnilimab, a novel PD-1 agonist monoclonal antibody, reduces T-cell proliferation and inflammatory cytokine secretion: results from a phase 1 clinical trial","volume":"18","author":"Luu","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.coph.2026.102635_bib58","doi-asserted-by":"crossref","first-page":"AB15","DOI":"10.1016\/j.jaad.2024.07.070","article-title":"Amlitelimab improves extent and severity of disease in adults with moderate-to-severe atopic dermatitis: 24-week results from a phase 2b trial","volume":"91","author":"Weidinger","year":"2024","journal-title":"J Am Acad Dermatol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489226000317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489226000317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:27:39Z","timestamp":1784910459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489226000317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":58,"alternative-id":["S1471489226000317"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2026.102635","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alopecia areata: Mechanisms, targeted therapies, and translational challenges","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2026.102635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102635"}}